Physician profile
Daniel J Ladd, JR.
NPI 1477556256
$1,861.12
in general payments reported to CMS, 2019-2025
23 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $134 · 2021: $30.52 · 2022: $161 · 2023: $69.71 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $725.55 | 2019-2023 | |
| Abbvie INC. | $143.16 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $102.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $99.07 | 2019-2021 | |
| Kerecis Limited | $94.23 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ucb, INC. | $79.77 | 2019-2025 | Bimzelx |
| Amgen INC. | $65.20 | 2025 | Otezla |
| Lilly USA, LLC | $61.23 | 2019-2022 | |
| Janssen Biotech, INC. | $58.79 | 2022-2025 | Tremfya |
| Journey Medical Corporation | $56.04 | 2019 | |
| Genentech USA, INC. | $49.81 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $43.36 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $43.03 | 2025 | Zoryve |
| Allergan, INC. | $41.83 | 2022 | |
| Boston Scientific Corporation | $38.53 | 2025 | Cds - Other |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.87 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $23.71 | 2025 | |
| Leo Pharma INC. | $20.73 | 2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.85 | 2025 | Cabtreo |
| Botanix Sb INC | $18.80 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $16.05 | 2019 | |
| Pfizer INC. | $14.58 | 2019 | |
| Galderma Laboratories, L.P. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.